Verona Pharma Says FDA Approved Ohtuvayre (Ensifentrine) For Maintenance Treatment Of Chronic Obstructive Pulmonary Disease In Adult Patients

6/26/24 4:59:51 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRNA alert in real time by email

Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.

The Company is fully staffed to launch and expects Ohtuvayre to be available in the third quarter 2024 through an exclusive network of accredited specialty pharmacies.

Get the next $VRNA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VRNA

Date	Price Target	Rating	Analyst
10/3/2024	$50.00	Overweight	Wells Fargo
5/22/2023	$35.00 → $38.00	Buy	Jefferies
9/19/2022	$27.00	Outperform	Wedbush
8/26/2022	$31.00	Overweight	Piper Sandler
11/12/2021	$18.00 → $23.00	Buy	Canaccord Genuity
9/13/2021	$25.00	Buy	HC Wainwright & Co.

More analyst ratings

$VRNA
Press Releases

Fastest customizable press release news feed in the world

Verona Pharma Announces December 2024 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 12:00 p.m. ET / 5:00 p.m. GMTLocation: New York, NY 7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Time: 3:00 p.m. ET / 8:00 p.m. GMTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information
11/19/24 2:00:00 AM ET
$VRNA
Biotechnology: Pharmaceutical Preparations
Health Care
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
11/7/24 7:00:00 AM ET
$AGEN
$LGND
$MRK
$TAK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Verona Pharma to Present at Jefferies London Healthcare Conference
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please contact: Verona Pharma plcTel: +1-844-341-9901Victoria Stewart, Senior Director of Investor Relations and [email protected] Partners(US Investor Enquiries)Tel: +1-212-600-1902verona@argotpartne
11/5/24 2:00:00 AM ET
$VRNA
Biotechnology: Pharmaceutical Preparations
Health Care

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
11/7/24 7:00:00 AM ET
$AGEN
$LGND
$MRK
$TAK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2024, and provides a corporate update. "We are pleased to report an exceptionally strong st
11/4/24 2:00:00 AM ET
$VRNA
Biotechnology: Pharmaceutical Preparations
Health Care
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States+1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Compan
10/21/24 2:00:00 AM ET
$VRNA
Biotechnology: Pharmaceutical Preparations
Health Care

Verona Pharma Says FDA Approved Ohtuvayre (Ensifentrine) For Maintenance Treatment Of Chronic Obstructive Pulmonary Disease In Adult Patients

Chat with this insight

Recent Analyst Ratings for $VRNA

$VRNA SEC Filings

SEC Form 10-Q filed by Verona Pharma plc

Verona Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Verona Pharma plc

$VRNA Press Releases

Fastest customizable press release news feed in the world

Verona Pharma Announces December 2024 Investor Conference Participation

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Verona Pharma to Present at Jefferies London Healthcare Conference

$VRNA Leadership Updates

Live Leadership Updates

$VRNA Market Insights

Live Market Insights

$VRNA Large Ownership Changes

This live feed shows all institutional transactions in real time.

$VRNA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$VRNA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$VRNA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$VRNA Financials

Live finance-specific insights

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

Canaccord Genuity Maintains Buy on Verona Pharma, Raises Price Target to $37

HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $36 Price Target

Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $38

Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

SEC Form SC 13G filed by Verona Pharma plc

Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

President and CEO Zaccardelli David sold $12,000 worth of Ordinary Shares (2,400 units at $5.00), decreasing direct ownership by 0.02% to 15,202,352 units (SEC Form 4)

Chief Financial Officer Hahn Mark W sold $12,000 worth of Ordinary Shares (2,400 units at $5.00), decreasing direct ownership by 0.02% to 14,291,336 units (SEC Form 4)

Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

Wells Fargo initiated coverage on Verona Pharma with a new price target

Jefferies resumed coverage on Verona Pharma with a new price target

Wedbush resumed coverage on Verona Pharma with a new price target

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Recent Analyst Ratings for
$VRNA

$VRNA
SEC Filings

$VRNA
Press Releases

$VRNA
Leadership Updates

$VRNA
Market Insights

$VRNA
Large Ownership Changes

$VRNA
Insider Trading

$VRNA
Insider Purchases

$VRNA
Analyst Ratings

$VRNA
Financials